↓ Skip to main content

Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report

Overview of attention for article published in Frontiers in oncology, April 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-PD-1 immunotherapy combined with stereotactic body radiation therapy and GM-CSF for the treatment of advanced malignant PEComa: A case report
Published in
Frontiers in oncology, April 2023
DOI 10.3389/fonc.2023.1045119
Pubmed ID
Authors

Yunfan Wang, Weiling Li, Xin Zuo, Ke Min, Yuehua Tang, Hong Chen, Weimin Wang, Yan Zhou

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 33%
Researcher 1 33%
Other 1 33%
Readers by discipline Count As %
Unspecified 1 33%
Immunology and Microbiology 1 33%
Medicine and Dentistry 1 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2023.
All research outputs
#17,824,825
of 26,171,302 outputs
Outputs from Frontiers in oncology
#8,104
of 22,919 outputs
Outputs of similar age
#248,767
of 421,752 outputs
Outputs of similar age from Frontiers in oncology
#372
of 1,220 outputs
Altmetric has tracked 26,171,302 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,919 research outputs from this source. They receive a mean Attention Score of 3.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,752 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,220 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.